NanoString Technologies (NASDAQ:NSTG) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NanoString Technologies (NASDAQ:NSTG – Get Rating) in a research report released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on NSTG. Morgan Stanley lowered their price objective on shares of NanoString Technologies from $17.00 to $16.00 and set an equal weight rating on the stock in a research report on Thursday, March 2nd. UBS Group assumed coverage on shares of NanoString Technologies in a research report on Thursday, February 2nd. They issued a buy rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, NanoString Technologies presently has an average rating of Moderate Buy and an average target price of $20.57.

NanoString Technologies Price Performance

NASDAQ:NSTG opened at $8.15 on Thursday. The firm’s fifty day moving average price is $10.27 and its 200 day moving average price is $10.05. NanoString Technologies has a 1-year low of $4.37 and a 1-year high of $37.06. The company has a current ratio of 4.87, a quick ratio of 4.14 and a debt-to-equity ratio of 4.95.

Insiders Place Their Bets

In related news, Director Gregory Norden bought 12,500 shares of the firm’s stock in a transaction on Tuesday, March 7th. The shares were bought at an average cost of $9.84 per share, for a total transaction of $123,000.00. Following the transaction, the director now owns 23,800 shares of the company’s stock, valued at $234,192. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Charles P. Waite, Jr. purchased 12,000 shares of the business’s stock in a transaction dated Monday, March 13th. The stock was acquired at an average price of $8.35 per share, with a total value of $100,200.00. Following the purchase, the director now directly owns 23,300 shares of the company’s stock, valued at approximately $194,555. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gregory Norden purchased 12,500 shares of the business’s stock in a transaction dated Tuesday, March 7th. The shares were purchased at an average cost of $9.84 per share, with a total value of $123,000.00. Following the purchase, the director now directly owns 23,800 shares in the company, valued at $234,192. The disclosure for this purchase can be found here. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. raised its stake in shares of NanoString Technologies by 28.4% during the 3rd quarter. RA Capital Management L.P. now owns 4,602,478 shares of the biotechnology company’s stock worth $58,774,000 after buying an additional 1,018,000 shares during the last quarter. Avidity Partners Management LP raised its stake in shares of NanoString Technologies by 194.6% during the 4th quarter. Avidity Partners Management LP now owns 2,057,200 shares of the biotechnology company’s stock worth $16,396,000 after buying an additional 1,359,000 shares during the last quarter. Invesco Ltd. raised its stake in shares of NanoString Technologies by 2.7% during the 1st quarter. Invesco Ltd. now owns 1,655,562 shares of the biotechnology company’s stock worth $57,531,000 after buying an additional 44,127 shares during the last quarter. Polar Capital Holdings Plc raised its stake in NanoString Technologies by 36.7% in the 1st quarter. Polar Capital Holdings Plc now owns 1,617,733 shares of the biotechnology company’s stock valued at $56,216,000 after purchasing an additional 434,081 shares during the last quarter. Finally, Platinum Investment Management Ltd. raised its stake in NanoString Technologies by 148.1% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,258,967 shares of the biotechnology company’s stock valued at $10,034,000 after purchasing an additional 751,562 shares during the last quarter.

About NanoString Technologies

(Get Rating)

NanoString Technologies, Inc engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular.